Drugs / RG6496
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07246941 | Nov 2025 → Feb 2028 expected | Huntington disease | Hoffmann-La Roche | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG6496 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246941 ↗ |
| Route | Intrathecal | “Intrathecally Administered RG6496” NCT07246941 ↗ |